Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Dec;55(12):2093-2095.
doi: 10.1093/rheumatology/kew053. Epub 2016 Mar 24.

The BSRBR-RA at 15 years

Elaine M Dennison  1   2 , Jon Packham  3 , Kimme Hyrich  4   5
Affiliations
Editorial

The BSRBR-RA at 15 years

Elaine M Dennison et al. Rheumatology (Oxford). 2016 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

ED had received speaking fees from Lilly. JP has received a personal fee for education from Abbvie. KH has received honoraria from Abbvie and honoraria and competitive grant funding from Pfizer.

References

    1. http://www.inflammation-repair.manchester.ac.uk/musculoskeletal/research...
    1. Hyrich KL, Watson KD, Silman AJ, Symmons D. Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology. 2006;45(12):1558–1565. - PubMed
    1. Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons D. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008;47(7):1000–5. - PMC - PubMed
    1. Hyrich K, Deighton C, Watson K, Symmons D, Lunt M, BSRBR_Control_Centre_Consortium, B Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) 2009;48(10):1323–7. - PMC - PubMed
    1. Hyrich K, Watson K, Lunt M, Symmons D, BSR Biologics_Register, B Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford) 2011;50(1):117–123. - PMC - PubMed

Publication types

MeSH terms

Substances